IYH is trading 3.29% up today as healthcare benefits from investor rotation away from technology amid elevated Treasury yields, geopolitical uncertainty, and renewed defensive positioning.
- Positive late-stage melanoma-vaccine results from Moderna and Merck are boosting sector-wide biotechnology and pharmaceutical optimism; Moderna is surging premarket and Merck is gaining roughly 7%–9%.
- The broader market is modestly higher as investors await the Federal Reserve’s July meeting minutes.
- Falling Treasury yields from Tuesday’s multi-year highs may also be supporting rate-sensitive healthcare stocks.